secwatch.observer — SEC 8-K summary
======================================

Issuer:     Petros Pharmaceuticals, Inc. (PTPI)
CIK:        0001815903
Form:       8-K
Filed at:   2022-01-21T23:59:59+00:00
Accession:  0001104659-22-006487
Event type: debt
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Petros subsidiary settles VIVUS disputes, issues $10.2M promissory note at 6% through 2027
--------------------------------------------------------------------------------

- Metuchen settles with VIVUS, forgives $9.6M in liabilities and retains ~$7.3M of API inventory.
- Issues $10,201,758 promissory note at 6% interest, payable quarterly from Apr 2022 to Jan 2027.
- License amended: VIVUS gets co-exclusive rights to Stendra but forbears from exercising unless default.
- Metuchen must pay $900k toward note and $1.54M for 2021 purchase order to release inventory.
- VIVUS granted right of first refusal on future debt/convertible equity financings until note paid in full.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815903/000110465922006487/0001104659-22-006487-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815903/000110465922006487/tm223291d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-006487

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer